Objective: To assess the efficacy of neoadjuvant systemic therapy (NST) at increasing the
rate of successful breast-conserving therapy (BCT) in triple negative breast cancer …

While historically breast cancer has been treated with primary surgery followed by adjuvant
therapy, the delivery of systemic therapy in the neoadjuvant setting has become increasingly …

The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously
over the past several years. Currently, NAT is the preferred option for high-risk early triple …

Objective It had been previously shown that patients who receive neoadjuvant systemic
therapy (NST) are more likely to undergo breast-conserving therapy (BCT) than those who …

Background Breast‐conserving surgery (BCS) in patients with large tumors shrunk by
neoadjuvant chemotherapy (NCT) remains controversial. We investigated oncologic …

With improvements in chemotherapy regimens, targeted therapies, and our fundamental
understanding of the relationship of tumor subtype and pathologic complete response …

Importance A recent publication reported that of 527 patients with clinically node-negative
(cN0) cT1/cT2 triple-negative breast cancer (TNBC) orERBB2-positive disease treated with …

Importance Image-guided breast biopsy of a residual imaging abnormality or tumor bed after
neoadjuvant chemotherapy (NACT) is increasingly used to assess residual cancer, facilitate …

Local treatment of the axilla in clinically node-negative (cN0) early breast cancer patients
with routine sentinel lymph node biopsy (SLNB) is debated after publication of ACOSOG …

Purpose Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer
treatment. One of the main goals of NACT is to reduce the extent of local surgery of the …